Ameritas Investment Partners’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Ameritas Investment Partners’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-470	Closed	-$4.27K	–	3243
2023 Q1	$4.27K	Hold	470	–	–	﹤0.01%	2888
2022 Q4	$7.77K	Hold	470	–	–	﹤0.01%	2859
2022 Q3	$9K	Hold	470	–	–	﹤0.01%	2839
2022 Q2	$11K	Hold	470	–	–	﹤0.01%	2821
2022 Q1	$23K	Hold	470	–	–	﹤0.01%	2506
2021 Q4	$33K	Hold	470	–	–	﹤0.01%	2393
2021 Q3	$44K	Hold	470	–	–	﹤0.01%	2249
2021 Q2	$47K	Hold	470	–	–	﹤0.01%	2234
2021 Q1	$44K	Hold	470	–	–	﹤0.01%	2165
2020 Q4	$39K	Hold	470	–	–	﹤0.01%	2132
2020 Q3	$40K	Buy	470 +33	+8%	+$3.85K	﹤0.01%	1982
2020 Q2	$41K	Hold	437	–	–	﹤0.01%	1956
2020 Q1	$12K	Buy	437 +190	+77%	+$7.39K	﹤0.01%	2464
2019 Q4	$10K	Hold	247	–	–	﹤0.01%	2748
2019 Q3	$3K	Hold	247	–	–	﹤0.01%	2998
2019 Q2	$9K	Buy	+247	New	+$13.4K	﹤0.01%	2838
2018 Q2	–	Sell	-63	Closed	-$7K	–	3071
2018 Q1	$7K	Hold	63	–	–	﹤0.01%	2817
2017 Q4	$8K	Hold	63	–	–	﹤0.01%	2819
2017 Q3	$6K	Hold	63	–	–	﹤0.01%	2905
2017 Q2	$8K	Buy	+63	New	+$8.5K	﹤0.01%	2878

Other funds holding VBIV

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameritas Investment Partners's VBIV Position: Q2 2023 in Review

Ameritas Investment Partners sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 470 shares — an estimated $4.27K sold.

Ameritas Investment Partners first reported a position in VBIV in Q2 2017 and held it in 20 quarters. The position peaked at $47K in Q2 2021. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

Ameritas Investment Partners reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
Ameritas Investment Partners sold 470 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $4.27K.
Ameritas Investment Partners first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2017 and held it in 20 quarters.
Ameritas Investment Partners's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $47K in Q2 2021.
46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on Ameritas Investment Partners's 13F filing for Q2 2023, filed 11 Aug 2023.